Current concepts in cervical pathology

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 5, 2009, Pages 729-738

  Park, Kay J ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CARCINOMA IN SITU; CYTOLOGY; GENOMICS; HISTOLOGY; HUMAN; INVASIVE CARCINOMA; PROGNOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; WART VIRUS; ADENOCARCINOMA; CANCER INVASION; DIFFERENTIAL DIAGNOSIS; FEMALE; METABOLISM; REVIEW; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

TUMOR MARKER;

ADENOCARCINOMA; CERVICAL INTRAEPITHELIAL NEOPLASIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 65649145718     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence,Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0. Lyon,France: IARC; 2004.
2. US Cancer Statistics Working Group. United States Cancer Statistics: 2004 Incidence andMortality. Atlanta, GA: DepartmentofHealthand Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007.
3. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 20036;348(6):518-527.
4. Robertson JH, Woodend B, Elliott H. Cytological changes preceding cervical cancer. J Clin Pathol. 1994;47(3):278-279.
5. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). Arch Pathol Lab Med. 2003;127(8):946-949.
6. Ismail SM, Colclough AB, Dinnen JS, et al. Observer variation in histopath- ological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298(6675):707-710.
7. Crum CP, Egawa K, Fu YS, et al. Atypical immature metaplasia (AIM): a subset of human papillomavirus virus infection of the cervix. Cancer. 1983;51(12):2214-2219.
8. Duggan MA, Akbari M, Magliocco AM. Atypical immature cervical metaplasia: immunoprofiling and longitudinal outcome. Hum Pathol. 2006;37(11):1473-1481.
9. Iaconis L, Hyjek E, Ellenson LH, Pirog EC. p16 and Ki-67 immunostaining in atypical immature squamous metaplasia of the uterine cervix: correlation with human papillomavirus detection [published correction appears in Arch Pathol Lab Med. 2008;132(1):13]. Arch Pathol Lab Med. 2007;131(9):1343-1349.
10. GengL,ConnollyDC,IsacsonC,RonnettBM,ChoKR.Atypicalimmature metaplasia(AIM) ofthecervix: is itrelated tohigh-gradesquamousintraepithelial lesion (HSIL)? Hum Pathol. 1999;30(3):345-351.
11. Ma L, FiskJM, Zhang RR, Ulukus EC, Crum CP, Zheng W. Eosinophilic dysplasia of the cervix: a newly recognized variant of cervical squamous intra-epithelial neoplasia. Am JSurgPathol. 2004;28(11):1474-1484.
12. Jaworski RC, Pacey NF, Greenberg ML, Osborn RA. The histologic diagnosis of adenocarcinoma in situ and related lesions of the cervix uteri: adeno- carcinoma in situ. Cancer. 1988;61:1171-1181.
13. Ostor AG, Duncan A, Quinn M, Rome R. Adenocarcinoma in situ of the uterinecervix: an experiencewith 100cases. GynecolOncol. 2000;79:207-210.
14. Denehy TR, Gregori CA, Breen JL. Endocervical curettage, cone margins, and residual adenocarcinoma in situ of the cervix. Obstet Gynecol. 1997;90:1-6.
15. Poynor EA, Barakat RR, Hoskins WJ. Management and follow-up of patients with adenocarcinoma in situ of the uterine cervix. Gynecol Oncol. 1995;57:158-164.
16. Andersen ES, Arffmann E. Adenocarcinoma in situ of the uterine cervix: a clinicopathologic study of 36 cases. Gynecol Oncol. 1989;35:1-7.
17. Bertrand M, Lickrish GM, Colgan TJ. The anatomic distribution ofcervical adenocarcinoma in situ: implications for treatment. Am JObstet Gynecol. 1987;157:21-25.
18. Muntz HG, Bell DA, Lage JM, Goff BA, Feldman S, Rice LW. Adenocar-cinoma in situ of the uterine cervix. Obstet Gynecol. 1992;80:935-939.
19. Ostor AG, Pagano R, Davoren RA, Fortune DW, Chanen W, Rome R. Ad- enocarcinomain situ ofthecervix. IntJGynecolPathol. 1984;3:179-190.
20. Qizilbash AH. In situ and microinvasive adenocarcinoma of the uterine cervix: a clinical, cytologic and histologic study of 14 cases. Am J Clin Pathol.1975;64:155-170.
21. Shin CH, Schorge JO, Lee KR, Sheets EE. Conservative management of adenocarcinoma in situ of the cervix. Gynecol Oncol. 2000;79:6-10.
22. Tobon H, Dave H. Adenocarcinomain situ ofthecervix: clinicopathologic observations of 11 cases. Int J Gynecol Pathol. 1988;7:139-151.
23. Wolf JK, Levenback C, Malpica A, Morris M, Burke T, Mitchell MF. Ade- nocarcinoma in situ of the cervix: significance of cone biopsy margins. ObstetGynecol. 1996;88:82-86.
24. Zaino RJ. Symposium part I: adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. Int J Gynecol Pathol.2002;21(4):314-326.
25. Goldstein NS, Mani A. The status and distance of cone biopsy margins as a predictor of excision adequacy for endocervical adenocarcinoma in situ. Am JClin Pathol. 1998;109:727-732.
26. Ostor AG, Pagano R, Davoren RAM, Fortune DW, Chanen W, Rome R. Adenocarcinoma in situ of the cervix. Int J Gynecol Pathol. 1984;3:179-190.
27. Park JJ, Sun D, Quade BJ, et al. Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia? Am J SurgPathol. 2000;24(10):1414-1419.
28. Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag; 2002:235-241.
29. Young RH, Clement PB. Pseudoneoplastic glandular lesions of the uterine cervix. Semin Diagn Pathol. 1991;8(4):234-249.
30. Lesack D, Wahab I, Gilks CB. Radiation-induced atypia of endocervical epithelium: a histological, immunohistochemical and cytometric study. Int J Gy-necol Pathol. 1996;15(3):242-247.
31. Oliva E, Clement PB, Young RH. Tubal and tubo-endometrioid metaplasia of the uterine cervix: unemphasized features that may cause problems in differential diagnosis: a report of 25 cases. Am J Clin Pathol. 1995;103(5):618-623.
32. Jaworski R. Endocervical glandular dysplasia, adenocarcinomain situ,and early invasive (microinvasive) adenocarcinoma of the uterine cervix. Semin DiagnPathol. 1990;7:190-205.
33. Brown LJ, Wells M. Cervical glandular atypia associated with squamous intraepithelial neoplasia: a premalignant lesion? J Clin Pathol. 1986;39:22-28.
34. Casper G, Ostor A, Quinn M. A clinicopathologic study of glandular dys- plasia of the cervix. Gynecol Oncol. 1997;64:166-170.
35. Gompel C, Silverberg S. Pathology in Gynecology and Obstetrics. Philadelphia, PA: JB Lippincott; 1994.
36. Ioffe OB, Sagae S, Moritani S, Dahmoush L, Chen TT, Silverberg SG. Proposal of a new scoring scheme for the diagnosis of noninvasive endocervicalglandular lesions. Am JSurgPathol. 2003;27(4):452-460.
37. RockJA, Jones HW, eds. Te Linde's Operative Gynecology. In press.
38. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamouscell carcinomaofthecervix: aGynecologicOncologyGroupstudy.Gynecol Oncol. 1990;38(3):352-357.
39. UrabeA, MatsumotoT, KimuraM, SonoueH, KinoshitaK. Gradingsystem of lymphatic invasion according to D2-40 immunostaining is useful for the prediction of nodal metastasis in squamous cell carcinoma of the uterine cervix.Histopathology. 2006;49(5):493-497.
40. Zaino RJ, Ward S, Delgado G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer. 1992;69(7):1750-1758.
41. Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. Arandomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1999;73(2):177-183.
42. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with radiation therapy: a multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer. 1991;67(11):2776-2785.
43. Shingleton HM, Orr JW, eds. Cancer of the Cervix. Philadelphia, PA: JB Lippincott; 1995.
44. Sedlis A, Sall S, Tsukada Y, et al. Microinvasive carcinoma of the uterine cervix: a clinical-pathologicstudy. Am JObstet Gynecol. 1979;133(1):64-74.
45. Burghardt E, Pickel H, Haas J, Lahousen M. Prognostic factors and operative treatment of stages IB to IIB cervical cancer. Am J Obstet Gynecol. 1987;156(4):988-996.
46. Kaspar HG, Dinh TV, Doherty MG, Hannigan EV, Kumar D. Clinical implicationsoftumorvolumemeasurementinstageIadenocarcinomaofthecervix. Obstet Gynecol. 1993;81(2):296-300.
47. Reich O, Pickel H. Multifocal stromal invasion in microinvasivesquamous cell carcinoma of the cervix: how to measure and stage these lesions. Int JGy-necol Pathol. 2002;21(4):416-417.
48. Ostor AG. Early invasive adenocarcinoma of the uterine cervix. Int J Gy-necol Pathol. 2000;19(1):29-38.
49. Tavassoli FA, Devilee P, eds. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003. World Health Organization Classifica-tion of Tumours.
50. Ishikawa M, Fujii T, Masumoto N, et al. Correlation of p16INK4A over- expression with human papillomavirus infection in cervical adenocarcinomas. Int J Gynecol Pathol. 2003;22(4):378-385.
51. Riethdorf L, Riethdorf S, Lee KR, Cviko A, Lconing T, Crum CP. Human papillomaviruses, expression of p16, and early endocervical glandular neoplasia.Hum Pathol. 2002;33(9):899-904.
52. Ansari-Lari MA, Staebler A, Zaino RJ, Shah KV, Ronnett BM. Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am JSurg Pathol. 2004;28(2):160-167.
53. Keating JT, Cviko A, Riethdorf S, et al. Ki-67, cyclin E, and p16INK4 arecomplimentary surrogate biomarkers for human papillomavirus-related cervicalneoplasia. Am JSurgPathol. 2001;25:884-891.
54. Horree N, Heintz AP, Sie-Go DM, van Diest PJ. p16 is consistently expressed in endometrial tubal metaplasia. Cell Oncol. 2007;29(1):37-45.
55. O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its valuein diagnosis. AdvAnatPathol. 2006;13(1):8-15.
56. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol. 1996;27(2):172-177.
57. Alkushi A, Irving J, Hsu F, et al. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch. 2003;442(3):271-277.
58. Bulten J, van der Laak JA, Gemmink JH, Pahlplatz MM, de Wilde PC, Hanselaar AG. MIB1, a promising marker for the classification of cervical intra-epithelial neoplasia. JPathol. 1996;178(3):268-273.
59. Pirog EC, Baergen RN, Soslow RA, et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostain-ing. Am JSurgPathol. 2002;26(1):70-75.
60. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002;41:185-207.
61. McCluggage WG, Maxwell P, McBride HA, Hamilton PW, Bharucha H. Monoclonal antibodies Ki-67 and MIB1 in the distinction of tuboendometrial metaplasia from endocervical adenocarcinoma and adenocarcinoma in situ in formalin-fixed material. Int J Gynecol Pathol. 1995;14(3):209-216.
62. Pirog EC, Isacson C, Szabolcs MJ, Kleter B, Quint W, Richart RM. Prolif-erative activity of benign and neoplastic endocervical epithelium and correlationwith HPVDNAdetection.IntJGynecolPathol.2002;21(1):22-26.
63. Chen Y, Miller C, Mosher R, et al. Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Res. 2003;63:1 927-1935.
64. Malinowski DP. Multiple biomarkers in molecular oncology: molecular diagnostics applications in cervical cancer detection. Expert Rev Mol Diagn.2007;7:117-131.
65. Santin AD, Zhan F, Bignotti E, et al. Gene expression profiles of primary HPV 16- and HPV 18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate biomarkers for cervical cancer diagnosis and therapy. Virology. 2005;331:269-291.
66. Kelly D, Kincaid E, Fansler Z, Rosenthal DL, Clark DP. Detection of cervical high-grade squamous intraepithelial lesions from cytologic samples usinga novel immunocytochemical assay (ProEx C). Cancer. 2006;108:494-500.
67. Shroyer KR, Homer P, Heinz D, Singh M. Validation of a novel immuno- cytochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression in cervical cytology. Cancer. 2006;108:324-330.
68. Shi J, Liu H, Wilkerson M, etal. Evaluation ofp16NK4a,minichromosome maintenance protein 2, DNA topoisomerase II alpha, ProE(X) C, and p16INK4a/ ProE(X) C in cervical squamous intraepithelial lesions. Hum Pathol. 2007;38: 1335-1344.
69. Badr RE, Walts AE, Chung F, Bose S. BD ProEX C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol. 2008;32:899-906.
70. Pinto AP, Schlecht NF, Woo TYC, Crum CP, Cibas ES. Biomarker (ProEx C, p16INK4a, and MiB-1) distinction of high-grade squamous intraepithelial lesionfrom its mimics. Mod Pathol. 2008;21:1067-1074.
71. Cooper K, Herrington CS, Stickland JE, Evans MF, McGee JO. Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isoto-pic in situ hybridisation. J Clin Pathol. 1991;44:990-996.
72. Evans MF, Mount SL, Beatty BG, Cooper K. Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol. 2002;15:1339-1347.
73. Guo M, Gong Y, Deavers M, et al. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J Clin Microbiol. 2008;46(1):274-280.
74. Dabic MM, Hlupic L, Babic D, Jukic S, Seiwerth S. Comparison of poly- merase chain reaction and catalyzed signal amplification in situ hybridization methods for human papillomavirus detection in paraffin-embedded cervical pre- neoplastic and neoplastic lesions. Arch Med Res. 2004;35:511-516.